VENUS REMEDIES
|
|
BOM : 526953     NSE : VENUSREM     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Oct 10,2024 |
Price(EOD): ₹ 336.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 451.38 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
VENUS REMEDIES | 3.4% | -7% | 46.4% |
SUN PHARMACEUTICAL INDUSTRIES | -1.2% | 2.8% | 71.4% |
CIPLA | -0.3% | -0.8% | 44.6% |
DR REDDYS LABORATORIES | -0.8% | -1% | 23% |
ZYDUS LIFESCIENCES | -0% | -5% | 76.5% |
DIVIS LABORATORIES | 9.6% | 9.4% | 60.9% |
FUNDAMENTAL ANALYSIS OF VENUS REMEDIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF VENUS REMEDIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
15.79
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 28.52 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 0.92
P/B Calculated based on Book Value of Rs 487.55 Cr
[Latest Year - Mar2024 - Consolidated Results ] 0.73
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 614.91 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
7% -37% 101% |
SHARE PRICE MOMENTUM OF VENUS REMEDIES
VENUS REMEDIES vs SENSEX
DEBT OF VENUS REMEDIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.08 0.08 0.09 0.08 |
0.08 0.09 0.1 0.09 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF VENUS REMEDIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF VENUS REMEDIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-44.35% -42.2% -60.79% -88.39% |
14.15% 8.27% 35.64% 3.39% |
QtrlyTrend |
0 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
VENUS REMEDIES related INDICES
You may also like the below Video Courses
FAQ about VENUS REMEDIES
Is VENUS REMEDIES good for long term investment?
As on Oct 10,2024, the Fundamentals of VENUS REMEDIES look Poor and hence it may not be good for long term investment ! See Financial Performance of VENUS REMEDIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is VENUS REMEDIES UnderValued or OverValued?
As on Oct 10,2024, VENUS REMEDIES is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of VENUS REMEDIES ?
As on Oct 10,2024, the Intrinsic Value of VENUS REMEDIES is Rs. 313.83 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 313.83
Fair Value [Median EV / Sales Model] : Rs. 533.59
Fair Value [Median Price / Sales Model] : Rs. 167.65
Estimated Median Fair Value of VENUS REMEDIES : Rs. 313.83
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.